drugset / Trial / NCT05683964

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

NCT05683964

NaSingle-groupOpen-labelDiagnostic

Summary

The goal of this research study is to determine whether hormonal therapies used early in the course of prostate cancer could increase the amount of Prostate-Specific Membrane Antigen (PSMA) as detected by PET/CT scans for participants with recurrent prostate cancer. This study will measure PSMA levels using standard PET/CT scans and participants will receive standard-of-care androgen receptor antagonist monotherapy. The names of the treatment interventions involved in this study are: * Androgen receptor antagonist monotherapy. * PSMA PET/CT scan It is expected that about 15 people will take part in this research study. Participation in this research study is expected to last about 4 weeks.

Timeline

Start
2023-01-19
Primary completion
2025-09-18
Completion
2026-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Apalutamide Small molecule
Subject Darolutamide Other / unclassified
Subject Enzalutamide Other / unclassified